1055306-89-2

Upstream product

• 198547-62-5 2-bromo-2,2-difluoro-N-(prop-2-en-1-yl)acetamide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1055306-76-7 1-(2,4-dimethoxyphenyl)-N-{[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methyl}-N-methylmethanamine 
• 1055306-87-0 tert-butyl {[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]methyl}methylcarbamate 
• 1055304-82-9 1-[4-fluoro-5-(2-fluoropyridin-3-yl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine 
• 1055306-65-4 (2RS)-3,3-difluoro-2-(2-fluoropyridin-3-yl)-2-hydroxy-4-methylidenepyrrolidine-1-carboxylate 
• 1055306-63-2 tert-butyl (4RS)-4-(bromomethyl)-3,3-difluoro-2-oxopyrrolidine-1-carboxylate 
• 1055306-88-1 tert-butyl {[4-fluoro-5-(2-fluoropyridin-3-yl)-1H-pyrrol-3-yl]methyl}methylcarbamate 
• 10130-74-2 m-Methoxybenzenesulfonyl chloride 

Downstream Products

• 1055305-20-8 1-{4-fluoro-5-(2-fluoropyridin-3-yl)-1-[(3-methoxyphenyl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine hydrochloride 

Relevant academic research and scientific papers

PYRROLE COMPOUNDS

The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity, which is represented by the formula (I) wherein R1 is an optionally substituted cyclic group, R2 is a substituent, R3 is an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a halogen atom, a cyano group or a nitro group, R4 and R5 are each a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a halogen atom, a cyano group or a nitro group, R6 and R6' are each a hydrogen atom or an alkyl group, and n is an integer of 0 - 3, or a salt thereof.